The Korea Times
amn_close.png
amn_bl.png
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
amn_bl.png
Business
  • Tech
  • Bio
  • Companies
amn_bl.png
Finance
  • Companies
  • Economy
  • Markets
  • Cryptocurrency
amn_bl.png
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to President
  • Letter to the Editor
amn_bl.png
Lifestyle
  • Travel & Food
  • Trends
  • People & Events
  • Books
  • Around Town
  • Fortune Telling
amn_bl.png
Entertainment & Arts
  • K-pop
  • Films
  • Shows & Dramas
  • Music
  • Theater & Others
amn_bl.png
Sports
amn_bl.png
World
  • SCMP
  • Asia
amn_bl.png
Video
  • Korean Storytellers
  • POPKORN
  • Culture
  • People
  • News
amn_bl.png
Photos
  • Photo News
  • Darkroom
amn_NK.png amn_DR.png amn_LK.png amn_LE.png
  • bt_fb_on_2022.svgbt_fb_over_2022.svg
  • bt_twitter_on_2022.svgbt_twitter_over_2022.svg
  • bt_youtube_on_2022.svgbt_youtube_over_2022.svg
  • bt_instagram_on_2022.svgbt_instagram_over_2022.svg
The Korea Times
amn_close.png
amn_bl.png
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
amn_bl.png
Business
  • Tech
  • Bio
  • Companies
amn_bl.png
Finance
  • Companies
  • Economy
  • Markets
  • Cryptocurrency
amn_bl.png
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to President
  • Letter to the Editor
amn_bl.png
Lifestyle
  • Travel & Food
  • Trends
  • People & Events
  • Books
  • Around Town
  • Fortune Telling
amn_bl.png
Entertainment & Arts
  • K-pop
  • Films
  • Shows & Dramas
  • Music
  • Theater & Others
amn_bl.png
Sports
amn_bl.png
World
  • SCMP
  • Asia
amn_bl.png
Video
  • Korean Storytellers
  • POPKORN
  • Culture
  • People
  • News
amn_bl.png
Photos
  • Photo News
  • Darkroom
amn_NK.png amn_DR.png amn_LK.png amn_LE.png
  • bt_fb_on_2022.svgbt_fb_over_2022.svg
  • bt_twitter_on_2022.svgbt_twitter_over_2022.svg
  • bt_youtube_on_2022.svgbt_youtube_over_2022.svg
  • bt_instagram_on_2022.svgbt_instagram_over_2022.svg
  • Login
  • Register
  • Login
  • Register
  • The Korea Times
  • search
  • all menu
  • Login
  • Subscribe
  • Photos
  • Video
  • World
  • Sports
  • Opinion
  • Entertainment & Art
  • Lifestyle
  • Finance
  • Business
  • National
  • North Korea
  • 1

    Discussions on raising age for free subway rides gain momentum

  • 3

    2-year work experience prerequisite lifted for foreign shipyard welders

  • 5

    US reaffirms nuclear security assurances to South Korea

  • 7

    Families of Itaewon victims on collision course with Seoul City

  • 9

    William Franklin Sands' diplomatic and undiplomatic views of late Joseon

  • 11

    Will KT, POSCO replace CEOs as Shinhan, Woori did?

  • 13

    Korea as sublime, strange, and familiar

  • 15

    TXT, Le Sserafim top Oricon album and singles chart

  • 17

    Chinese spy balloon 'transits' Latin America after first craft flies over US

  • 19

    Blinken scraps rare China trip over alleged spy balloon

  • 2

    INTERVIEWTati Gabrielle, actress of Korean, African-American descent, feels proud of her heritage

  • 4

    Families of Itaewon crowd stampede victims clash with police over installation of memorial altar

  • 6

    China expresses 'strong dissatisfaction' over US shooting down balloon

  • 8

    Opposition party takes to streets to protest prosecution probes into leader

  • 10

    Korean American Rep. Young Kim named chair of House Indo-Pacific subcommittee

  • 12

    US remains committed to using full range of capabilities to defend S. Korea: Blinken

  • 14

    US shoots down suspected Chinese spy balloon with a single missile

  • 16

    Wang Yi urges US to 'avoid misjudgment' over balloon controversy

  • 18

    President Yoon at odds with politician who helped him win election

  • 20

    Musk didn't defraud investors with 2018 Tesla tweets

Close scrollclosebutton

Close for 24 hours

Open
  • The Korea Times
  • search
  • all menu
  • Login
  • Subscribe
  • Photos
  • Video
  • World
  • Sports
  • Opinion
  • Entertainment & Art
  • Lifestyle
  • Finance
  • Business
  • National
  • North Korea
Business
Bio
  • Tech
  • Bio
  • Companies
Mon, February 6, 2023 | 22:13
[INTERVIEW] Korea should strengthen ecosystem for clinical trials
INTERVIEWKorea should strengthen ecosystem for clinical trials
Over the last few years, the government has been supporting its strategy to help the country rise as a biotechnology hub in Asia given Korea's long-time competiveness in product manufacturing. The country's advantages in terms of having excellent infrastructure, workforce and IT platform have truly been beneficial amid COVID-19 as a number of biotechnology companies, includin...
Kim Yoo-chul | 2022-06-02 15:24
Samsung Biologics establishes one-stop mRNA vaccine production capability at Songdo plant
Samsung Biologics establishes one-stop mRNA vaccine production capability at Songdo plant
Samsung Biologics, the biotech arm of Korea's Samsung Group, has established a one-stop production capability for manufacturing messenger RNA (mRNA) vaccines by newly adding an mRNA vaccine substance production facility at the plant, a company official said Thursday.
2022-06-02 11:21
[INTERVIEW] Immunomic Therapeutics CEO expects meaningful test results for brain tumor drug
INTERVIEWImmunomic Therapeutics CEO expects meaningful test results for brain tumor drug
William Hearl, CEO of Immunomic Therapeutics, the U.S. subsidiary of the Korean biotech company, HLB, said that the company expects meaningful test results from its Phase 2 clinical trials of a drug for glioblastoma by August of this year at the latest.
Baek Byung-yeul | 2022-05-26 16:03
HLB gets positive Phase 3 data with liver cancer treatment
HLB gets positive Phase 3 data with liver cancer treatment
HLB has taken a step closer to the global commercialization of its anticancer treatment Rivoceranib as it secured statistical significance in Phase 3 global clinical trials of the drug, according to the local biotech company, Sunday.
Baek Byung-yeul | 2022-05-15 16:23
Lotte seeks to acquire US CMO plant to enter bioindustry
Lotte seeks to acquire US CMO plant to enter bioindustry
Lotte Group is in the process of acquiring a bioindustry contract manufacturing (CMO) plant in the U.S., according to the investment banking industry, Thursday. The move comes after the conglomerate declared the bioindustry as its new growth engine. CMOs specialize in producing biopharmaceuticals developed by other companies.
Kim Hyun-bin | 2022-05-05 14:46
CHA Biotech's US subsidiary opens CDMO plant in Texas
CHA Biotech's US subsidiary opens CDMO plant in Texas
Matica Biotechnology, a U.S. affiliate of CHA Biotech, has opened a cell and gene therapy manufacturing facility in College Station, Texas, according to the cell therapeutics and stem cell developer affiliate of CHA Medical & Bio Group, Wednesday.
Lee Kyung-min | 2022-05-04 15:53
Osstem Implant posts record profits for Q1
Osstem Implant posts record profits for Q1
Osstem Implant posted a record operating profit for the first quarter, the dental equipment manufacturer said Friday.
Baek Byung-yeul | 2022-04-29 16:30
HLB posts earnings surprise in Q1
HLB posts earnings surprise in Q1
Local biotech company HLB posted sales and operating profit records for the first quarter. The company announced on April 25 that its quarterly sales rose a whopping 1,052 percent from the same period in 2021 to 63.4 billion won ($50.8 million). Its operating profit also came to 18.8 billion won to turn into a surplus. Both sales and operating profit figures were the highest ...
Baek Byung-yeul | 2022-04-26 15:12
Moon hails Phase 3 trial of SK Bioscience's COVID-19 vaccine
Moon hails Phase 3 trial of SK Bioscience's COVID-19 vaccine
President Moon Jae-in praised a successful Phase 3 trial of the nation's first homegrown COVID-19 vaccine, developed by SK Bioscience, Tuesday.
2022-04-26 15:09
Yoon to visit headquarters of homegrown COVID-19 vaccine
Yoon to visit headquarters of homegrown COVID-19 vaccine
President-elect Yoon Suk-yeol will visit homegrown vaccine producer SK Bioscience on Monday and emphasize vaccine sovereignty amid the country's fight against the novel coronavirus, his spokesperson said.
2022-04-25 10:58
1234 5 67
Top 10 Stories
12-year work experience prerequisite lifted for foreign shipyard welders 2-year work experience prerequisite lifted for foreign shipyard welders
2Families of Itaewon victims on collision course with Seoul City Families of Itaewon victims on collision course with Seoul City
3President Yoon at odds with politician who helped him win election President Yoon at odds with politician who helped him win election
49 fishermen, including 2 Vietnamese, missing in boat incident 9 fishermen, including 2 Vietnamese, missing in boat incident
5LG publishes Korea's first group-level net zero report LG publishes Korea's first group-level net zero report
6[VIDEO] Filipina K-pop idol and K-drama actress react to stereotypes about the Philippines VIDEOFilipina K-pop idol and K-drama actress react to stereotypes about the Philippines
7Conflict reignites over relocation of POSCO Holdings to Pohang Conflict reignites over relocation of POSCO Holdings to Pohang
8FSC approves security token transactions in Korea FSC approves security token transactions in Korea
9Hyundai Motor's technology helps team become WTCR double champion Hyundai Motor's technology helps team become WTCR double champion
10Tasks lie ahead for Woori's next chairman nominee picked amid controversy Tasks lie ahead for Woori's next chairman nominee picked amid controversy
DARKROOM
  • Nepal plane crash

    Nepal plane crash

  • Brazil capital uprising

    Brazil capital uprising

  • Happy New Year 2023

    Happy New Year 2023

  • World Cup 2022 Final - Argentina vs France

    World Cup 2022 Final - Argentina vs France

  • World Cup 2022 France vs Morocco

    World Cup 2022 France vs Morocco

CEO & Publisher : Oh Young-jin
Digital News Email : webmaster@koreatimes.co.kr
Tel : 02-724-2114
Online newspaper registration No : 서울,아52844
Date of registration : 2020.02.05
Masthead : The Korea Times
Copyright © koreatimes.co.kr. All rights reserved.
  • About Us
  • Introduction
  • History
  • Contact Us
  • Products & Services
  • Subscribe
  • E-paper
  • RSS Service
  • Content Sales
  • Site Map
  • Policy
  • Code of Ethics
  • Ombudsman
  • Privacy Statement
  • Terms of Service
  • Copyright Policy
  • Family Site
  • Hankook Ilbo
  • Dongwha Group